Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Xenical Study Supports Proposed Nonprescription Dose, Glaxo Says

This article was originally published in The Tan Sheet

Executive Summary

The "behavior modification" effect ofXenical adverse events could help allay concerns that OTC availability would lead to people using orlistat without making appropriate adjustments to their diets, according to the principal investigator of a study on the drug
Advertisement

Related Content

Xenical Short-Term Switch Odds Slimmer Than Long-Term – Experts
Xenical Short-Term Switch Odds Slimmer Than Long-Term – Experts
Xenical Short-Term Switch Odds Slimmer Than Long-Term – Experts
Xenical Switch Proposal Will Face Advisory Committee Review In January
Xenical Switch Proposal Will Face Advisory Committee Review In January
Xenical OTC Actual Use Trial Shows Dose Compliance, Glaxo Says
Clarke To Oversee Glaxo Consumer Division During Xenical Switch Bid
GSK Sees Big Opportunity In OTC Diet Aids: Xenical Switch NDA Filed
Xenical Rx-To-OTC Switch In The Works, GSK/Roche Announce
Xenical Rx-To-OTC Switch In The Works, GSK/Roche Announce

Topics

Advertisement
UsernamePublicRestriction

Register

PS098767

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel